VIDEO: Port delivery system maintains improvements in diabetic retinopathy at 2 years
Click Here to Manage Email Alerts
In this Healio Video Perspective from the ASRS meeting, Margaret Chang, MD, MS, of Retinal Consultants Medical Group presents 2-year results for the port delivery system with ranibizumab.
The phase 3 Pavilion trial, involving 174 patients, investigated the platform for the treatment of nonproliferative diabetic retinopathy.
“PDS was able to maintain [Diabetic Retinopathy Severity Score] improvements achieved at year 1 through week 100 with 9-month refill intervals,” Chang said. “Patients who crossed over from the control group to PDS maintained or improved their DRSS score from baseline.”